Skip to Main Content
Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Evolving Tactics With Inhibition of Sodium-Glucose Cotransporters

Evolving Tactics With Inhibition of Sodium-Glucose Cotransporters
Evolving Tactics With Inhibition of Sodium–Glucose Cotransporters
Where Does Combination Therapy With an SGLT2 Inhibitor Plus a DPP-4 Inhibitor Fit in the Management of Type 2 Diabetes?
February 12 2015
https://doi.org/10.2337/dc14-2517
Evolving Tactics With Inhibition of Sodium–Glucose Cotransporters
Blood Pressure Reduction: An Added Benefit of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes
February 12 2015
https://doi.org/10.2337/dc14-1596
Evolving Tactics With Inhibition of Sodium–Glucose Cotransporters
SGLT2 Inhibitors: The Latest “New Kids on the Block”!
February 12 2015
https://doi.org/10.2337/dc14-3048
Evolving Tactics With Inhibition of Sodium–Glucose Cotransporters
Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes
January 29 2015
https://doi.org/10.2337/dc14-2365
Evolving Tactics With Inhibition of Sodium–Glucose Cotransporters
Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial
January 15 2015
https://doi.org/10.2337/dc14-0666
Evolving Tactics With Inhibition of Sodium–Glucose Cotransporters
Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
January 12 2015
https://doi.org/10.2337/dc14-2364
Evolving Tactics With Inhibition of Sodium–Glucose Cotransporters
Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
December 02 2014
https://doi.org/10.2337/dc14-1237
Evolving Tactics With Inhibition of Sodium–Glucose Cotransporters
Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin
October 28 2014
https://doi.org/10.2337/dc14-1142
Evolving Tactics With Inhibition of Sodium–Glucose Cotransporters
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
September 30 2014
https://doi.org/10.2337/dc14-1096
Evolving Tactics With Inhibition of Sodium–Glucose Cotransporters
Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
September 30 2014
https://doi.org/10.2337/dc13-2955
Evolving Tactics With Inhibition of Sodium–Glucose Cotransporters
Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy
September 11 2014
https://doi.org/10.2337/dc14-0890
Evolving Tactics With Inhibition of Sodium–Glucose Cotransporters
Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study
September 09 2014
https://doi.org/10.2337/dc13-2762
  • Online ISSN 1935-5548
  • Print ISSN 0149-5992

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept